Medical Management of Patients with an Acute Stroke: Treatment and Prevention

REFERENCES

• Broderick J, Brott T, Kothari R, et al. The Greater Cincinnati/Northern Kentucky Stroke Study: Preliminary first-ever and total incidence rates of stroke among Blacks. Stroke. 1998;29:415–521.
   PubMed Web of Science ®Google Scholar
• Brown RD, Whisnant JP, Sicks JD, O'Fallon WM, Wiebers DO. Stroke incidence, preva-lence, and survival: secular trends in Rochester, Minnesota through 1989. Stroke. 1996; 27:373–380.
   PubMed Web of Science ®Google Scholar
• Alberts MJ, Perry A, Dawson DV, Bertels C. Effects of public and professional education on reducing the delay in presentation and referral of stroke patients. Stroke. 1992;23:352–356.
   PubMed Web of Science ®Google Scholar
• Engelstein E, Margulies J, Jeret JS. Lack of t-PA use for acute ischemic stroke in a community hospital: high incidence of exclusion criteria. Am] Emerg Med. 2000;18(3):257–260.
   PubMed Web of Science ®Google Scholar
• Working Group on Emergency Brain Resuscitation. Emergency brain resuscitation. Ann Int Med. 1995;122:622–627.
   PubMed Web of Science ®Google Scholar
• The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581–1587.
   PubMed Web of Science ®Google Scholar
• Albers GW, Bates VE, Clark WM, Bell R, Verro P, Hamilton SA. Intravenous tissue-type plas-minogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA. 2000; 283:1145–1150.
   PubMed Web of Science ®Google Scholar
• The NINDS t-PA Stroke Study Group. I ntracerebra I hemorrhage after intravenous t-PA therapy for ischemic stroke. Stroke. 1997;28:2109–2118.
   PubMed Web of Science ®Google Scholar
• The NINDS t-PA Stroke Study Group. Generalized efficacy of t-PA for acute stroke: Subgroup analysis of the NINDS t-PA Stroke Trial. Stroke. 1997;28:2119–2125.
   PubMed Web of Science ®Google Scholar
• Marler J, Tilley B. Lu M, et al. Early stroke treat-ment associated with better outcome: The NINDS rt-PA Stroke Study. Neurology. 2000; 55:1649–1655.
   PubMed Web of Science ®Google Scholar
• Jaillard A, Cornu C, Durieux A, Moulin T, Boutitie F, Lees KR, Hommel M. Hemorrhagic transformation in acute ischemic stroke. The MAST-E study. MAST-E Group. Stroke. 1999; 30(7):1326–1332.
   PubMed Web of Science ®Google Scholar
• Alberts Mi. tPA in acute ischemic stroke: United States experience and issues for the future. Neurology. 1998;51\(suppl 3):553–55.
   Google Scholar
• Morris D, Rosamond WD, Madden KP, et al. Prehospital and emergency department delays after acute stroke. Stroke. 2000;31:2585–2590.
   PubMed Web of Science ®Google Scholar
• Alberts MJ, Hademenos G, Latchaw RE, et al. Recommendations for the establishment of pri-mary stroke centers. Brain Attack Coalition. JAA4A. 2000;283(23):3102–3109.
   Google Scholar
• Morgenstern L, Staub L, Chan W, et al. Improving delivery of acute stroke therapy. Stroke. 2002;33:160–166.
   PubMed Web of Science ®Google Scholar
• Hacke W, Kaste M, Fieschi C, et al., for the Second European-Australasian Acute Stroke Study Investigators. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet 1998;352:1245–1251.
   PubMed Web of Science ®Google Scholar
• Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S. Recombinant tis-sue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset The ATLANTIS Study: a randomized con-trolled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAA4A. 1999;282: 2019–2026.
   Web of Science ®Google Scholar
• Weitz J, Leslie B, Ginsberg J. Soluble fibrin degradation products potentiate tissue plas-minogen activator-induced fibrinogen proteoly-sis. IC/in Invest. 1991;87:1082–1090.
   PubMed Web of Science ®Google Scholar
• Stewart R, Fredenburgh J, Leslie B, et al. Identification of the mechanism responsible for the increased fibrin specificity of TN K-tissue plasminogen activator relative to tissue plas-minogen activator. I Biol Chem. 2000;275: 10112–10120.
   Web of Science ®Google Scholar
• Lyden P, on behalf of the TNK for Stroke Investigators. Pilot study of tenecteplase (TNK) in acute sichemic stroke: preliminary report [abstract]. Stroke. 2003;34:246.
   Web of Science ®Google Scholar
• AbESTT Investigators. Effects of Abciximap for acute ischemic stroke: final results of Abciximap in emergent stroke treatment trial (AbESTT) [abstract]. Stroke 2003;34:253.
   Web of Science ®Google Scholar
• Furlan A, Higashida R, Wechsler L, et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thrombo-embol ism. JAMA. 1999;282(21):2003–2011.
   PubMed Web of Science ®Google Scholar
• Lisboa RC, Jovanovic BD, Alberts Mi. Analysis of the safety and efficacy of intra-arterial throm-bolytic therapy in ischemic stroke. Stroke. 2002;33(12):2866–2871.
   PubMed Web of Science ®Google Scholar
• Fisher M. Developing therapy for acute ischemic stroke. Therapie. 2002;57(6):564–568.
   PubMed Web of Science ®Google Scholar
• Green AR. Why do neuroprotective drugs that are so promising in animals fail in the clinic? An industry perspective. Clin Exp Pharmacol Physiol. 2002;29(11):1030–1034.
   PubMed Web of Science ®Google Scholar
• Dorman PJ, Sandercock PAG. Considerations in the design of clinical trials of neuroprotec-tive therapy in acute stroke. Stroke. 1996;27:1507–1515.
   PubMed Web of Science ®Google Scholar
• Stroke Therapy Academic Industry Roundtable (STAIR). Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke. 1999;30: 2752–2758.
   PubMed Web of Science ®Google Scholar
• Georgiadis D, Schwarz S, Aschoff A, Schwab S. Hemicraniectomy and moderate hypothermia in patients with severe ischemic stroke. Stroke. 2002;33(6):1584–1588.
   PubMed Web of Science ®Google Scholar
• Georgiadis D, Schwarz S, Kollmar R, Schwab S. Endovascular cooling for moderate hypothermia in patients with acute stroke: first results of a nov-el approach. Stroke. 2001;32(11):2550–2553.
   PubMed Web of Science ®Google Scholar
• Adams H, Adams R, Brott T, et al. Guidelines for the early management of patients with ischemic stroke. Stroke. 2003;34:1056–1083.
   PubMed Web of Science ®Google Scholar
• Hachinski V. Intravenous heparin in acute stroke. Arch Neurol. 1999;59:1162.
   Google Scholar
• Sandercock P. Is there still a role for intravenous heparin in acute stroke? No. Arch Neurol. 1999;56:1160–1161.
   PubMed Web of Science ®Google Scholar
• Sandercock P. Intravenous unfractionated heparin in patients with acute ischemic stroke: a treatment to be used in the context of ran-domized trials only. Stroke. 2001;32:579.
   PubMed Web of Science ®Google Scholar
• Sandercock P, Gubitz G, Counsell C, et al. Immediate anticoagulation therapy for acute ischemic stroke. Part 1: A systemic review of 21 randomized trials of anticoagulant vs. control, including 23,374 patients [abstract]. Stroke. 1999;30:248.
   Google Scholar
• Adams H. Emergent use of anticoagulation for treatment of patients with ischemic stroke. Stroke. 2002;33:856–861.
   PubMed Web of Science ®Google Scholar
• Rordorf G, Koroshetz WJ, Ezzeddine MA, Segal AZ, Buonanno FS. A pilot study of drug-induced hypertension for treatment of acute stroke. Neurology. 2001;56(9):1210–1213.
   PubMed Web of Science ®Google Scholar
• Schwarz S, Georgiadis D, Aschoff A, Schwab S. Effects of induced hypertension on intracranial pressure and flow velocities of the middle cere-bral arteries in patients with large hemispheric stroke. Stroke. 2002;33(4):998–1004.
   PubMed Web of Science ®Google Scholar
• CAST (Chinese Acute Stroke Trial) Collaborative Group. CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet. 1997;349: 1641–1649.
   PubMed Web of Science ®Google Scholar
• International Stroke Trial Collaborative Group. The International Stroke Trial (1ST): a random-ized trial of aspirin, subcutaneous heparin, both, or neither among 19,435 patients with acuteischemicstroke.Lancet.1997;349:1569–1581.
   PubMed Web of Science ®Google Scholar
• Alberts MJ, Brass LM. Assessment of early deterioration. I Stroke Cerebrovasc Dis. 1999;8:171–175.
   PubMedGoogle Scholar
• Brown DL, Haley EC. Post-emergency depart-ment management of stroke [review]. Emerg Med Clin North Am. 2002;20(3):687–702.
   PubMed Web of Science ®Google Scholar
• Qureshi Al, Suarez JI, Yahia AM, et al. Timing of neurologic deterioration in massive middle cerebral artery infarction: a multicenter review. Crit Care Med. 2003;31(1):272–277.
   PubMed Web of Science ®Google Scholar
• Swanson RA. Intravenous heparin for acute stroke. Neurology. 1999;52:1746–1750.
   PubMed Web of Science ®Google Scholar
• McGuire JR, Harvey RL. The prevention and management of complications after stroke. Phys Med Rehabil Clin North Am. 1999;10(4): 857–874, ix.
   PubMedGoogle Scholar
• Hillbom M, Erila T, Sotaniemi K, et al. Enoxaparin vs. heparin for prevention of deep-vein thrombosis in acute ischemic stroke: a ran-domized, double-blind study. Ada Neurol Scand. 2002;106:84–92.
   PubMed Web of Science ®Google Scholar
• Leizorovicz A, Simonneau G, Decousis H, Boissel JP. Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: a meta-analysis. BMJ. 1994;309:299–304.
   PubMed Web of Science ®Google Scholar
• Alberts MJ, Horner J, Gray L, Brazer SR. Aspiration after stroke: lesion analysis by brain MRI. Dysphagia. 1992;7(3):170–173.
   PubMedGoogle Scholar
• Horner J, Massey EW, Rishi JE, Lathrop DL, Chase KN. Aspiration following stroke: clinical correlates and outcome. Neurology. 1988;38: 1359–1362.
   PubMed Web of Science ®Google Scholar
• Addington W, Stephens R, Gilliland K, et al. Assessing the laryngeal cough reflex and the risk of developing pneumonia after stroke. Arch Phys Med RehabiL 1999;80:150–154.
   PubMed Web of Science ®Google Scholar
• Bath PM, Bath FJ, Smithard DG. Interventions for dysphagia in acute stroke. Cochrane Database Systematic Rev. 2000;(2):CD000323.
   PubMedGoogle Scholar
• Norton B, Homer-Ward M, Donnelly M, et al. A randomised prospective comparision of per-cutaneous endoscopic gastrostomy and naso-gastric tube feeding after acute dysphagic stroke. BMJ. 1996;312:13–16.
   PubMed Web of Science ®Google Scholar
• O'Neill PA. Swallowing and prevention of com-plications. Brit Med Bull. 2000;56(2):457–465.
   PubMed Web of Science ®Google Scholar
• Kolin A, Norris J. Myocardial damage from acute cerebral lesions. Stroke. 1984;15:990–993.
   PubMed Web of Science ®Google Scholar
• James P, Ellis CJ, Whitlock RM, McNeil AR, Henley J, Anderson NE. Relation between tro-ponin T concentration and mortality in patients presenting with an acute stroke: observational study. BMJ. 2000;320(7248):1502–1504.
   PubMed Web of Science ®Google Scholar
• Powers WJ. Acute hypertension after stroke: the scientific basis for treatment decisions. Neurology. 1993;43:461–467.
   PubMed Web of Science ®Google Scholar
• Bhalla A, Wolfe CD, Rudd AG. Management of acute physiological parameters after stroke. Q J Med. 2001;94(3):167–172.
   Google Scholar
• Davenport RJ, Dennis MS, Wellwood I, Warlow CP. Complications after acute stroke. Stroke. 1996;27:415–420.
   PubMed Web of Science ®Google Scholar
• van der Worp HB, Kappelle LJ. Complications of acute ischaemic stroke. Cerebrovasc Dis. 1998;8:124–132.
   PubMed Web of Science ®Google Scholar
• Hier DB, Foulkes MA, Swiontoniowski M, et al. Stroke recurrence within 2 years after ischemic infarction. Stroke. 1991;22:155–161.
   PubMed Web of Science ®Google Scholar
• Sacco RL, Shi TS, Zamanillo MC, Kargman DE. Predictors of mortality and recurrence after hos-pitalized cerebral infarction in an urban com-munity: The Northern Manhattan Stroke Study. Neurology. 1994;44:626–634.
   PubMed Web of Science ®Google Scholar
• Gorelick PB, Sacco RL, Smith DB, et al. Prevention of a first stroke: a review of guide-lines and a multidisciplinary consensus state-ment from the National Stroke Association. JAA4A. 1999;281:1112–1120.
   Web of Science ®Google Scholar
• The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuret-ic. JAA4A. 2002;288:2981–2997.
   Web of Science ®Google Scholar
• Wing L, Reid C, Ryan P, et al. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med. 2003;348:583–592.
   PubMed Web of Science ®Google Scholar
• Bosch J, Yusuf S, Pogue J, et al. Use of ramipril in preventing stroke: double blind randomised trial. BMJ. 2002;324:1–5.
   PubMed Web of Science ®Google Scholar
• PROGRESS Collaborative Group. Randomised trial of perindopril-based blood pressure-lower-ing regimen among 6105 individuals with pre-vious stroke or transient ischaemic attack. Lancet. 2001;358:1033–1041.
   PubMed Web of Science ®Google Scholar
• Sacco RL, Benjamin EJ, Broderick JP, et al. American Heart Association Prevention Conference, IV: prevention and rehabilitation of stroke: risk factors. Stroke. 1997;28:1507–1517.
   PubMed Web of Science ®Google Scholar
• Wolf PA, Clagett P, Easton JD, et al. Preventing ischemic stroke in patients with prior stroke and transient ischemic attack: a statement for healthcare professionals from the Stroke Council of the American Heart Association. Stroke. 1999;30:1991–1994.
   PubMed Web of Science ®Google Scholar
• Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI. A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med. 2001;345:1243–1249.
   PubMed Web of Science ®Google Scholar
• Writing Group for the Women's Health Initiative Randomized Controlled Trial. Risks and benefits of estrogen plus progestin in healthy post-menopausal women. JAMA. 2002;288:321–333.
   PubMed Web of Science ®Google Scholar
• CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348:1329–1339.
   PubMed Web of Science ®Google Scholar
• Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study 2. Didyridamole and acetyl-salicyclic acid in the secondary prevention of stroke. Neurol Sci. 1996;143:1–13.
   Web of Science ®Google Scholar
• Hass WK, Easton JD, et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med. 1989;321:501–507.
   PubMed Web of Science ®Google Scholar
• SALT Collaborative Group. Swedish Aspirin Low-Dose Trial (SALT) of 75 mg of aspirin as second-ary prophylaxis after cerebrovascular ischaemic events. Lancet. 1991;338:1345–1349.
   PubMed Web of Science ®Google Scholar
• The Canadian Cooperative Study Group. A ran-domized trial of aspirin and sulfinpyrazone in threatened stroke. N Engl J Med. 1978;299: 53–59.
   PubMed Web of Science ®Google Scholar
• Ezekowitz MD, Bridgers SL, James KE, Carliner NH, Colling CL, Gornick CC, for the Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. Warfarin in the prevention of stroke associated with non-rheumatic atrial fibrillation. N Engl J Med. 1992;327:1406–1412.
   PubMed Web of Science ®Google Scholar
• Albers GW, Amarenco P, Easton DJ, Sacco RL, Teal P. Antithrombotic and thrombolytic therapy for ischemic stroke. Chest. 2001;119:300S–320S.
   Google Scholar
• Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Int Med. 1994;154:1449–1457.
   PubMed Web of Science ®Google Scholar
• Stroke Prevention in Atrial Fibrillation Investigators. Predictor of thromboembolism in atrial fibrillation. II. Echocardiograhic features of patients at risk. Ann Intern Med. 1992;116:6–12.
   PubMed Web of Science ®Google Scholar
• Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for pre-vention of thromboembolism in atrial fibrilla-tion: Stroke Prevention in Atrial Fibrillation ll Study. Lancet. 1994;343:687–691.
   PubMed Web of Science ®Google Scholar
• Brass LM, Krumholz HM, Scinto J, Radford Mi. Use of warfarin among hospitalized Medicare patients with atrial fibrillation [abstract]. Stroke. 1997;28:237.
   Google Scholar
• Brass LM, Krumholz HM, Scinto JM, Radford M. Warfarin use following ischemic stroke among Medicare patients with atrial fibrillation. Arch Int Med. 1998;158: 2093–2100.
   PubMed Web of Science ®Google Scholar
• Brass LM, Krumholz HM, Scinto JM, Radford M. Warfarin use among patients with atrial fib-rillation. Stroke. 1997;28:2382–2389.
   PubMed Web of Science ®Google Scholar
• Bungard Ti, Ghali WA, Teo KK, McAlister FA, Tsuyuki RT. Why do patients with atrial fibrilla-tion not receive warfarin? Arch Intern Med. 2000;160:41–46.
   PubMed Web of Science ®Google Scholar
• Mohr JP, Thompson JLP, Lazar RM, et al., for the Warfarin-Aspirin Recurrent Stroke Study Group. A comparision of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med. 2001;345:1444–1451.
   PubMed Web of Science ®Google Scholar
• Blauw GJ, Lagaay AM, Smelt AH, Westendorp RG. Stroke, statins, and cholesterol. A meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors. Stroke. 1997;28(5):946–950.
   PubMed Web of Science ®Google Scholar
• Byington RP, Davis BR, Plehn JF, et al., for the PPP Investigators. Reduction in stroke events with pravastatin. The Prospective Pravastatin Pooling (PPP) Project Circulation. 2001;103: 387–392.
   Google Scholar
• LIPID Study Group. Design features and base-line characteristics of the LIPID (Long-Term Intervention with Pravastatin in Ischemic Disease) study: a randomized trial in patients with previous acute myocardial infarction and/or unstable angina pectoris. Am] Cardiol. 1995;76:474–479.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Rifai N, Pfeffer MA, et al., for the Cholesterol and Recurrent Events (CARE) Investigators. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients wtih average cholesterol levels. Circulation. 1998;98:839–844.
   PubMed Web of Science ®Google Scholar
• Sacks FM, Pfeffer MA, Moye LE, et al. The effect of pravastatin on coronary events after myocar-dial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001–1009.
   PubMed Web of Science ®Google Scholar
• The LIPID Study Group. Prevention of cardio-vascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med. 1999;339:1349–1357.
   Web of Science ®Google Scholar
• Straus S, Majurndar S, McAlister F. New evi-dence for stroke prevention. JAMA. 2002;288: 1388–1395.
   PubMed Web of Science ®Google Scholar
• Bath PM, Lindenstrom E, Boysen G, et al. Tinzaparin in acute ischaemic stroke (TAIST): a randomised aspirin-controlled trial. Lancet. 2001;358(9283):702–710.
   PubMed Web of Science ®Google Scholar
• Gordon DL, Linhardt R, Adams HP Jr. Low-molecular-weight heparins and heparinoids and their use in acute or progressing ischemic stroke. Clin NeuropharmacoL 1990;13:522–543.
   PubMed Web of Science ®Google Scholar